GLUE (Monte Rosa Therapeutics) Moat Score: 5/10 (As of Jul. 13, 2026)


GLUE Monte Rosa Therapeutics Inc GLUE
34 GF Score
Price $23.02
! 5 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics Moat Score?

Monte Rosa Therapeutics GLUE -6.04% 34 Moat Score is 5 as of Jul. 13, 2026. GuruFocus rates GLUE with a GF Score™ of 34/100. The stock has 5 warning signs investors should review. Among 1,396 Biotechnology companies, Monte Rosa Therapeutics ranks better than 96.7% on this metric.

Monte Rosa Therapeutics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Monte Rosa Therapeutics has Narrow Moat: Monte Rosa Therapeutics has valuable intellectual property and patents in the biotech sector. While it shows strong R&D capabilities, it faces competition and lacks significant market share.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Monte Rosa Therapeutics might have Narrow Moat - Solid narrow moat.

Monte Rosa Therapeutics  (NAS:GLUE) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Monte Rosa Therapeutics Moat Score Related Terms

GLUE vs SNDX, IOVA, TYRA: Moat Score Comparison

For the Biotechnology subindustry, Monte Rosa Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monte Rosa Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Monte Rosa Therapeutics's Moat Score falls into.


GLUE
34GF Score
Monte Rosa Therapeutics Inc GLUE
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Monte Rosa Therapeutics (GLUE) has a Moat Score of 5 as of Jul. 13, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Monte Rosa Therapeutics ranks #46 out of 1396 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Monte Rosa Therapeutics' Moat Score too high?
Monte Rosa Therapeutics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Monte Rosa Therapeutics' value of 5 is 150% above this industry median. Based on the distribution chart, Monte Rosa Therapeutics ranks #46 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Monte Rosa Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' Moat Score compare to SNDX and IOVA?
According to the Biotechnology industry distribution chart, Monte Rosa Therapeutics ranks #46 out of 1396 companies for Moat Score. This places Monte Rosa Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Monte Rosa Therapeutics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monte Rosa Therapeutics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monte Rosa Therapeutics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current Moat Score of 5. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Monte Rosa Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current Moat Score is 5 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
34GF Score

Get the complete analysis for GLUE

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.02
Price